Multinational phase 2 study of atezolizumab, vemurafenib, and cobimetinib for CNS metastases of melanoma

Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. The phase 2 TRICOTEL study (65 patients of 21 centers in 7 countries) found that the combination of atezolizumab, vemurafenib, and cobimetinib resulted in intracranial objective response in 42% (95% CI 29-54) of patients with BRAF^V600-mutated melanoma. The combination had promising intracranial and extracranial activity in this patient cohort.